Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
about
Progress towards mechanism-based treatment for Diamond-Blackfan anemiaMedical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis.Iron chelation therapy in myelodysplastic syndromes.Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingDurable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndromeHematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia majorHematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC studyPhysiology and pathophysiology of iron in hemoglobin-associated diseases.Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.Efficacy and safety of deferasirox in myelodysplastic syndromes.Review of therapeutic options and the management of patients with myelodysplastic syndromes.Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.Iron chelation in the treatment of cancer: a new role for deferasirox?An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?Treatment of Myelofibrosis: Old and New Strategies.A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndromeErythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells.Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosisUpdate on the use of deferasirox in the management of iron overload.Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice.Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes.Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia.Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
P2860
Q26823710-EAB20A14-EDA2-473F-8062-D301BBF64123Q33420358-372E554C-61BD-4D27-985F-F5852436E697Q33692856-17A5C4FB-C04C-49E5-A1DA-D88CE6D02BECQ34002840-EBF103FC-61DA-4EFF-B4AB-06A86A60E7CFQ34032208-5B659620-BFEB-4846-A780-0A2DBAEA3B6DQ35414429-7CB77E84-F676-4984-A96A-EFF0166BB2A8Q35743810-AFFBA4F9-8696-4D8E-824C-1495521EEA16Q36216214-2A0D2864-381E-4373-80F7-677D99A5F041Q36862483-64945E3B-E0F4-448B-BD78-B9CE1CECDD4DQ36967110-968EDB5B-77D2-4F74-88E5-E440DC3BABFAQ37082896-19A281FE-9318-47E6-97C0-FA0077F8BE92Q37833060-DE68CB4E-7F90-4AA4-8778-87001B031B07Q38082464-172C3565-04C2-457B-8C19-4F8367E3B8FEQ38095121-6155228E-B3BF-4E3C-BDD4-4B7C73A05186Q38101043-37E22828-970B-417F-8FED-4C0A7CAA3AA2Q38112400-B7F758F0-10A8-416F-9720-D143C24B6194Q38368123-699BE25F-4BA9-4E39-80F6-E0AEDD722A31Q38832241-AC2A8E9F-A948-47A9-B4A5-89A42BBDAF14Q38836181-2EEEED6E-4B8C-4D01-A355-173FBFAE8C57Q39349869-23569370-D332-4485-84EF-DA14EAC98924Q39698504-3BEE7C1B-AC2A-4D5F-83A3-98FAEFEECC99Q39819964-BC6AC232-AF74-42FF-B291-893B4B6FF97EQ40210444-01D16460-DCE1-4907-8D06-A37C9086E4F0Q40639096-17671BB8-4E5C-421F-9CA1-5C69468E7C46Q40892218-3E4419AF-415D-4213-98B1-481852E9C6F3Q41077865-96E71B1C-3DBE-45D9-BDC0-DACCA8E61B4DQ41980585-62E8ABC2-8585-40D9-B3D7-264F3BADF01FQ42117340-B14EE672-82EF-4757-B3F2-01B10B8D7C2CQ42664574-6FBA27E6-9B9C-4B3F-895C-EFFA52A8A82DQ43459542-B921CE3F-56A6-4084-B7EE-D9C1BA94BEEAQ43934706-BD3D30A9-F596-425F-B267-3E3DBEEF2DE1Q45132809-8A38F302-CCE8-4A0A-9FF1-71E4F1634FA3Q45971495-7BD7A805-D8E2-482C-A715-72F8C4A0D75CQ47159669-81D47F35-3594-4675-A09A-592B809E3E07Q47864152-0D514353-E7D2-46BF-AFF4-B9B1689A358BQ50484280-161B573B-C1BB-4B60-8D8C-AA30C18B1C8CQ50500444-41D615E4-7EA6-4735-8D54-B283EBBABF04
P2860
Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@en
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@nl
type
label
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@en
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@nl
prefLabel
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@en
Deferasirox treatment improved ...... ome and primary myelofibrosis.
@nl
P2093
P50
P356
P1433
P1476
Deferasirox treatment improved ...... rome and primary myelofibrosis
@en
P2093
P356
10.1159/000158631
P577
2008-10-01T00:00:00Z